Source: Clinical Edge
October 1, 2004
By:
Rondo P. Middleton, PhD, Steven S. Hannah, PhD
While osteoarthritis is perceived as a structural disease, the underlying pathology and chronic changes occur at a cellular and molecular level. In this article, we will discuss recent research involving the molecular mechanisms involved in osteoarthritis and newer opportunities for treatment. Key to this knowledge are research tools emerging from the scientific disciplines of functional genomics and molecular biology.
|
Source: Clinical Edge
October 1, 2004
By:
Mark Waldron, PhD
Osteoarthritis is a chronic and potentially debilitating disease involving the disruption of metabolic homeostasis within the articular chondrocyte. Specifically, osteoarthritis involves an increased ratio of cartilage-degrading enzymes (matrix metalloproteinases, or MMPs) to their normal inhibitors, tissue inhibitors of metalloproteinases (TIMPs). It is the imbalance of TIMPs and MMPs that contributes to the pathologic breakdown of cartilage. Dietary fatty acids can help to correct this imbalance by modulating the production of inflammatory mediators.
|
Source: Clinical Edge
October 1, 2004
By:
Dottie P. Laflamme, DVM, PhD, DACVN
Osteoarthritis, or degenerative joint disease, is the most prevalent joint disorder in dogs. Mild osteoarthritis may cause subtle gait changes or intermittent lameness. As osteoarthritis severity progresses, the dog may become less active, show visible lameness, experience difficulty rising or lying down, express pain, or experience difficulty posturing to urinate or defecate.
|
Source: Clinical Edge
October 1, 2004
By:
Dottie P. Laflamme, DVM, PhD, DACVN
Osteoarthritis, also called degenerative joint disease, is the most prevalent joint disorder in dogs, affecting as many as 20% of adult dogs. Osteoarthritis is associated with inflammation and increased degradation or loss of proteoglycans from the extracellular matrix, resulting in a morphologic breakdown in articular cartilage.
|
|
